Value: The company’s patented Early Bird Bleed Monitoring System for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding complications immediately, improving patient outcomes and lowering healthcare costs. These procedures are commonly performed by Interventional Cardiologists, Vascular Surgeons and Interventional Radiologists. The system has a low-risk regulatory profile, and Saranas has recently submitted for FDA clearance via the de novo pathway and no clinical trials. In addition to pursuing strategic business partnerships, Saranas is prepared to conduct a clinical pilot launch of the Early Bird Bleed Monitoring System into select hospitals throughout the US and the Texas Medical Center in 2018 in order to demonstrate clinical utility, performance and the potential for reduction in complication frequency and associated costs. The company has perfected and protected its technology, shown excellent traction, has a well developed timeline, and favorable timing to get in the marketplace with a strong multiple ROI.